|GC-MS/MS ANALYSIS OF BENZODIAZEPINES USING ANALYTE PROTECTANTS|
Jeremy Matthews, Alex Chen, Flavio Bedini
Purpose: Assess the feasibility of using analyte protectants to improve the analysis of benzodiazepines.
|Targeted cancer therapy based on blocking the expression of genes and small doses of oxaliplatin.|
Bavykin A.S.1, Korotaeva A.A.1, Poyarkov S.V.2, Syrtsev A.V.1, Karpukhin A.V.1
The major drawbacks of the prescribed chemotherapy, are still remain the significant side effects and drug - resistance. Even targeted chemotherapy by means of specific antibodies do not always help to solve these complications. Our purpose was to identify potential biological targets associated with the development of drug resistance and to develop a specific method of suppressing the viability of cancer cells exposed to low doses of standard chemotherapy.
|Inverted Y Approach to Lumbosacral region - Analysis of 525 cases over 10 years|
Dr Krishna Kumar and Dr Renjith Kumar
Traditional approach to lumosacral region utilizes midline incision, which often requires long incision to get sufficient exposure. We describe our experience with inverted Y approach to lumbosacral junction.
|LC/MS/MS Quantitation of Eicosapentaenoic Acid in Rat Plasma|
Rachel Sun, Jordan Nally, Tim Shoaf
Eicosapentaenoic acid (EPA) is an omega-3 fatty acid, which has been documented to be important in biochemical and physiological processes including inflammatory response, blood clotting and the immune system. Eicosapentaenoic acid (EPA) appears in different forms in the blood including triglyceride, ethyl ester, or free acid. In this work we presented an LC/MS/MS method to quantitate the total eicosapentaenoic acid in rat plasma with a 96-well plate format.
|Comparison of Dissociated Phoria Measuring Methods. Repeatability and Reliability|
Ane Murueta-Goyena Larrañaga
The aim of this study is to determine the reliability and compare reproducibility of different dissociated phoria measure tests.
|Secondary Prevention of Stroke: The role of the General Practitioner|
This study aims to review the literature to further elucidate the potential impact of primary care physicians in reducing the burden of stroke.
|Participation in “The Airways Program” (TAP) and Associated Mortality Reduction|
Pradeep Paul George, Bee Hoon Heng, Mavis Yeow Bee Ling, Loo See Yeow, Fong Seng Lim, Lim Tow Keang
Research objectives were to assess the impact of “The air way program” on patients length of stay, readmission and mortality.
|Random Homozygous Gene Perturbation (RHGP) as a Tool for Target Discovery and Validation|
Wu-Bo Li and Michael Goldblatt
Random homozygous gene perturbation (RHGP) can identify and validate any host (cellular) gene target that directly causes a desired phenotype without requiring prior knowledge of the target. The central feature of RHGP is a unique lentiviral-based genetic element, known as a gene search vector (GSV) designed to interrogate the entire genome and identify target genes that cause the phenotype of interest.
|Gene expression analysis of CD14+ monocytes immunomagnetically separated directly from whole blood: adaptation of protocols towards clinical trial requirements|
Gregor Winkels1, Ines Dischinger1, Katharina Bublitz1, Evert Luesink2, Nanguneri R. Nirmala2, Frank Staedtler2, Keith J. Johnson2, Alena Fitz1, Sabrina Schmitz1, Dirk Dietrich1, Sonja Balzer1, Sabine Classen1, Silvia Rüberg1, Uwe Janssen1, and Bernhard Gerstmayer1
Peripheral blood is widely used as starting material for biomarker discovery and validation using molecular biology technologies. The vast majority of currently published transcriptome data is based on RNA derived either from stabilized whole blood or peripheral blood mononuclear cells (PBMCs). Here, gene expression profiling studies and SOPs for fast, easy and specific manual or automated isolation of monocytes directly from whole blood are being described.
|Quality Standards for 14C API for use in human clinical studies|
I Shaw, G Johnston, K Dare, D Dams
The Good Manufacturing Practice (GMP) state that the active pharmaceutical ingredient (API) intended for use in early stage clinical trials should be of "suitable" quality. The Clinic Ready quality standard ensures that the API is synthesised with all the appropriate documentation to facilitate QP release of the final IMP for guman clinical dosing.
|<<|| 1 2 3 4 || >>|
|Showing Results 1 - 10 of 39||